Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1410284
This article is part of the Research Topic Gastric Cancer: Individualized Immunotherapeutic Approaches and Biomarker-Driven Strategies View all articles

SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: a case report

Provisionally accepted
Jike Hu Jike Hu Xuemei Li Xuemei Li Yunpeng Wang Yunpeng Wang Bo Xu Bo Xu Puyi He Puyi He Zhuanfang Wang Zhuanfang Wang Lijuan He Lijuan He Hao Chen Hao Chen *
  • Lanzhou University Second Hospital, Lanzhou, Gansu Province, China

The final, formatted version of the article will be published soon.

    Gastric cancer is highly prevalent in China, yet early diagnosis and overall survival rates are low.The primary treatment strategy is comprehensive therapy centered on surgery. Studies indicate that neoadjuvant chemotherapy can enhance radical resection rates and extend survival in locally advanced gastric cancer. Combining VEGFR inhibitors with chemotherapy improves efficacy in digestive system tumors, while PD-1/PD-L1 inhibitors combined with antiangiogenesis agents or chemotherapy show synergistic effects. This report presents a case of gastric adenocarcinoma (cT3N1M0) treated with SOX, apatinib mesylate, and camrelizumab as neoadjuvant therapy, followed by D2 distal gastrectomy and postoperative adjuvant therapy with the same regimen. The patient completed all treatment cycles successfully. Post-neoadjuvant therapy, only focal residual cancer cells were found in the lamina propria (pT1a). During postoperative adjuvant therapy follow-up, gastroscopic biopsy indicated a pathological complete response with no recurrence or metastasis. The patient primarily experienced dyspepsia, oropharyngeal pain, capillary proliferation, mild bone marrow suppression, nausea, and vomiting as side effects. Therefore, SOX combined with apatinib mesylate and camrelizumab shows promise for treating resectable locally advanced gastric cancer.

    Keywords: Sox, Apatinib mesylate, camrelizumab, Locally advanced gastric cancer, case report

    Received: 31 Mar 2024; Accepted: 28 Jun 2024.

    Copyright: © 2024 Hu, Li, Wang, Xu, He, Wang, He and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Hao Chen, Lanzhou University Second Hospital, Lanzhou, 730030, Gansu Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.